Bipolar Disorder

Bipolar Disorder – High‑Yield Study Guide for Medical Students

Definition

Bipolar disorder is a chronic mood disorder characterized by recurrent episodes of abnormally elevated mood and energy (mania or hypomania), typically alternating with episodes of major depression. It is divided into two main subtypes:

• Bipolar I disorder: at least one lifetime manic episode, with or without depressive episodes.
• Bipolar II disorder: at least one hypomanic episode and one major depressive episode, with no history of full mania.

Both subtypes cause significant functional impairment, high relapse rates, and increased suicide risk, requiring long‑term mood stabilizing treatment.

Epidemiology

Understanding epidemiology helps frame exam questions and clinical suspicion:

• Lifetime prevalence:
  • Bipolar I: roughly 0.6–1% of the population.
  • Bipolar II: approximately 0.4–1%.
• Age of onset: usually late adolescence to early adulthood (15–30 years). Earlier onset is associated with a more severe course.
• Sex distribution: overall similar between males and females. Bipolar I shows slight male predominance; bipolar II and rapid cycling are more common in females.
• Course: chronic, episodic, with high recurrence; most patients spend more time in depressive than manic/hypomanic states.
• Comorbidity: high rates of anxiety disorders, substance use disorders, ADHD, and personality disorders.
• Suicide risk: markedly elevated compared with the general population; bipolar disorder is among the psychiatric diagnoses with the highest suicide rate.

Pathophysiology

The pathophysiology of bipolar disorder is multifactorial and not fully elucidated. Key components to remember for exams include:

Genetic and Familial Factors

• High heritability: estimates up to 70–80%. First‑degree relatives of individuals with bipolar disorder have an increased risk of bipolar and unipolar mood disorders.
• Polygenic contribution: multiple susceptibility loci, overlapping partially with schizophrenia and major depressive disorder.

Neurotransmitter Dysregulation

• Monoaminergic systems:
  • Altered regulation of dopamine, serotonin, and norepinephrine.
  • Mania is often associated with increased dopaminergic and noradrenergic activity and reduced GABAergic inhibitory tone.
  • Depressive states show relative monoamine deficits.
• Glutamate–GABA balance: hyperglutamatergic and hypo‑GABAergic states may contribute to mood instability and excitotoxicity.

Neuroendocrine and Circadian Abnormalities

• HPA axis dysregulation with abnormal cortisol rhythms, similar to major depression but often more labile.
• Circadian rhythm disruption: sleep–wake dysfunction and altered melatonin secretion; circadian genes likely affect susceptibility and cycling patterns.

Neuroanatomical and Functional Changes

• Structural and functional imaging studies show changes in the prefrontal cortex, amygdala, hippocampus, and anterior cingulate cortex.
• Abnormal connectivity between limbic emotion‑processing regions and prefrontal regulatory networks may underlie mood lability and impaired impulse control.

Clinical Presentation

Bipolar disorder presents clinically with episodes of mania, hypomania, and depression. Recognizing the distinct syndromes is critical for diagnosis and treatment choice.

Manic Episode (Bipolar I)

Core concept: distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally increased energy or goal‑directed activity lasting at least 1 week (or any duration if hospitalization is required).

• DSM‑style symptom cluster: During the mood disturbance, at least three (four if mood is only irritable) of the following:
  • Grandiosity or inflated self‑esteem (e.g., believes they have special powers or talents).
  • Decreased need for sleep (e.g., feels rested after 3 hours).
  • Pressured speech: more talkative than usual or feels pressure to keep talking.
  • Flight of ideas or subjective racing thoughts.
  • Distractibility: attention too easily drawn to irrelevant external stimuli.
  • Increased goal‑directed activity (social, work/school, sexual) or psychomotor agitation.
  • Excessive involvement in risky activities (spending sprees, sexual indiscretions, foolish investments, substance use).
• Functional impact: marked impairment in social or occupational functioning, necessitates hospitalization to prevent harm to self or others, or involves psychotic features.
• Psychosis: mood‑congruent or mood‑incongruent delusions and hallucinations can occur in severe mania.

Hypomanic Episode (Bipolar II and Others)

Core concept: similar symptom constellation and quality of mood as mania, but less severe and lasting at least 4 consecutive days.

• Symptoms are observable by others and represent a clear change from baseline.
• No marked functional impairment, no hospitalization required, and no psychotic features. Presence of psychosis automatically defines mania.
• Patients may subjectively enjoy hypomanic periods, which can delay help‑seeking.

Major Depressive Episode in Bipolar Disorder

Bipolar depression is clinically similar to unipolar major depression but requires different treatment strategies and carries high risk of misdiagnosis.

• At least 2 weeks of depressed mood or anhedonia plus associated symptoms:
• Symptoms include:
• Sleep disturbance (often hypersomnia, but insomnia also common).
• Appetite or weight change.
• Psychomotor agitation or retardation.
• Fatigue or loss of energy.
• Feelings of worthlessness or excessive guilt.
• Impaired concentration or indecisiveness.
• Recurrent thoughts of death, suicidal ideation, plans, or attempts.
• Functional impairment is prominent; suicidality must always be assessed.
• Bipolar depression may show features such as psychomotor retardation, atypical features (hypersomnia, hyperphagia), and a history of early onset and high recurrence.

Other Course Specifiers and Presentations

• Rapid cycling: at least four mood episodes (major depressive, manic, hypomanic) in 12 months; associated with greater treatment resistance and worse prognosis.
• Mixed features: concurrent manic/hypomanic and depressive symptoms (e.g., depressed mood with motor agitation and racing thoughts).
• Seasonal pattern and peripartum onset specifiers can be applied, similar to major depressive disorder.

Diagnosis

Diagnosis of bipolar disorder is clinical and based on a thorough psychiatric history, including longitudinal course and collateral information. Laboratory and imaging tests help exclude medical or substance‑induced causes.

Core Diagnostic Principles

• Bipolar I disorder:
  • Requires at least one manic episode.
  • Major depressive episodes are common but not required for diagnosis.
• Bipolar II disorder:
  • Requires at least one hypomanic episode and at least one major depressive episode.
  • No history of full mania; if mania occurs, the diagnosis changes to bipolar I.

History and Mental Status Examination

• Carefully assess past episodes of elevated mood, decreased need for sleep, impulsivity, and associated functional impairment.
• Obtain collateral information from family/partners, as patients may lack insight into hypomanic or even manic episodes.
• Evaluate for psychotic features (delusions, hallucinations) and their temporal relationship to mood symptoms.
• Screen for substance use, which may mimic or exacerbate mood symptoms.

Rule‑Outs and Differential Diagnosis

• Substance/medication‑induced mood disorder: mood symptoms temporally related to drugs (e.g., stimulants, corticosteroids, antidepressants).
• Medical conditions: hyperthyroidism, Cushing’s syndrome, neurologic disorders (e.g., temporal lobe epilepsy), infectious or autoimmune encephalitis.
• Schizoaffective disorder, bipolar type: psychosis occurs for at least 2 weeks in the absence of prominent mood symptoms.
• Borderline personality disorder: affective instability is typically more rapid and reactive to interpersonal stressors, without discrete episodes lasting days to weeks with clear euthymic intervals.
• Major depressive disorder: no history of mania or hypomania; important to reassess history over time.
• ADHD and other impulse‑control disorders: more chronic, non‑episodic impulsivity and distractibility.

Screening Tools and Rating Scales

• Mood Disorder Questionnaire (MDQ): screening tool for bipolar disorder, especially in primary care and outpatient settings.
• Young Mania Rating Scale (YMRS): used to quantify severity of manic symptoms and monitor treatment response.
• Hamilton Depression Rating Scale (HDRS) or PHQ‑9: can track depressive symptoms but do not distinguish unipolar vs bipolar depression.

Laboratory and Ancillary Work‑Up

No lab test confirms bipolar disorder, but baseline investigations are important for safety and exclusion of organic causes:

• Baseline labs prior to pharmacotherapy: CBC, CMP, renal and liver function tests, fasting lipids and glucose, thyroid function tests.
• Urine toxicology screen to evaluate for substance use.
• Pregnancy test in women of childbearing potential before starting medications such as valproate, carbamazepine, or lithium.
• Additional testing (e.g., neuroimaging) if neurologic signs, atypical course, or late onset.

Management

Management of bipolar disorder involves acute treatment of mood episodes and long‑term maintenance to prevent relapse and minimize functional impairment. Treatment is multimodal, combining pharmacotherapy, psychoeducation, and psychosocial interventions.

General Principles

• Avoid antidepressant monotherapy in bipolar disorder due to risk of switching into mania, hypomania, or mixed states.
• Use mood stabilizers and certain atypical antipsychotics as first‑line agents.
• Choose medications based on predominant polarity (mania vs depression), comorbidities, side‑effect profile, past response, and safety considerations (e.g., pregnancy, renal function).
• Emphasize maintenance therapy, as high relapse rates are seen when mood stabilizers are discontinued.

Acute Management of Mania/Hypomania

Management varies by severity, presence of psychosis, and risk of harm.

• First‑line options for acute mania often include:
  • Lithium: classic mood stabilizer; effective for acute mania and relapse prevention, and has anti‑suicidal properties.
  • Valproate (divalproex sodium/valproic acid): particularly useful in mixed states, rapid cycling, and dysphoric mania.
  • Atypical antipsychotics (e.g., quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone): effective for acute mania and psychosis; some have mood‑stabilizing properties for maintenance.
• Combination therapy: Lithium or valproate plus an atypical antipsychotic is often used for severe mania or mania with psychotic features.
• Adjunctive benzodiazepines (e.g., lorazepam) may be used short‑term for agitation, insomnia, or catatonic features.
• Avoid or discontinue antidepressants during manic or mixed episodes.

Acute Management of Bipolar Depression

Bipolar depression is frequent and disabling, and treatment differs from unipolar depression. Avoid antidepressant monotherapy and aim to use agents with proven efficacy in bipolar depression.

• First‑line options (depending on guidelines and jurisdiction) often include:
  • Quetiapine (monotherapy): effective for acute bipolar depression and maintenance at certain doses.
  • Lurasidone (monotherapy or adjunctive to lithium/valproate): approved in several regions for bipolar depression.
  • Lithium: particularly useful in patients with high suicide risk or prominent episodic pattern; often combined with other agents.
  • Lamotrigine: more robust evidence for prevention of depressive episodes; also used in acute bipolar depression, especially in less severe cases and as an adjunct.
• Antidepressants (e.g., SSRIs, bupropion) may be considered only in combination with a mood stabilizer and generally after first‑line bipolar‑specific agents have been tried, given the risk of mood switch.
• Consider ECT (electroconvulsive therapy) for severe, treatment‑resistant, psychotic, or life‑threatening (e.g., suicidality, refusal to eat/drink) bipolar depression or mania.

Maintenance Treatment

Maintenance therapy aims to prevent recurrence of mania and depression, reduce subsyndromal symptoms, and improve functioning.

• Lithium:
  • Gold standard for maintenance, with strong evidence for reducing relapse and suicidality.
  • Requires regular monitoring of serum levels, renal function, thyroid function, and electrolytes.
• Valproate:
  • Effective for maintenance in patients with predominant mania, rapid cycling, or mixed features.
  • Monitor liver function and platelets; teratogenicity is a major concern in women of childbearing potential.
• Lamotrigine:
  • Particularly useful for prevention of depressive episodes and in bipolar II disorder.
  • Titrate slowly to minimize risk of rash and Stevens–Johnson syndrome.
• Atypical antipsychotics (e.g., quetiapine, olanzapine, aripiprazole, long‑acting injectable formulations):
  • Useful in patients with psychotic features, poor lithium response, or adherence issues.
  • Monitor for metabolic syndrome, extrapyramidal side effects, and prolactin changes depending on agent.
• Combination regimens: common in patients with partial response or complex illness course (e.g., lithium plus lamotrigine, or mood stabilizer plus antipsychotic).

Psychosocial and Non‑Pharmacologic Interventions

• Psychoeducation:
  • Teaches patients (and families) about illness course, early warning signs, medication adherence, sleep hygiene, and triggers.
• Cognitive‑behavioral therapy (CBT):
  • Targets maladaptive thoughts and behaviors; can reduce depressive symptoms and improve adherence.
• Interpersonal and social rhythm therapy (IPSRT):
  • Focuses on stabilizing daily routines and circadian rhythms; useful for preventing relapse.
• Family‑focused therapy:
  • Addresses expressed emotion and improves communication and problem‑solving within the family.
• Supportive therapy and group interventions: provide ongoing support and help address comorbid substance use or psychosocial stressors.

Monitoring and Safety

• Regularly assess for suicidal and homicidal ideation, especially during mood transitions and depressive episodes.
• Monitor for medication side effects and long‑term complications (e.g., lithium‑induced nephropathy or hypothyroidism, valproate‑related hepatotoxicity, antipsychotic‑induced metabolic syndrome).
• Reinforce adherence and address barriers (side effects, insight, stigma).
• Encourage sleep hygiene and avoidance of substances such as alcohol, stimulants, and recreational drugs that can destabilize mood.

Key Clinical Pearls for Exams and Practice

• Any history of mania = bipolar I, regardless of number or severity of depressive episodes.
• Bipolar II requires both hypomania and major depression, and cannot have a past manic episode.
• Always differentiate bipolar depression from unipolar depression; misdiagnosis leads to inappropriate antidepressant monotherapy and risk of mood switches or rapid cycling.
• Antidepressant monotherapy is generally contraindicated in bipolar I disorder and should be avoided in bipolar II unless carefully combined with a mood stabilizer.
• Lithium is the classic mood stabilizer with strong evidence for suicide risk reduction. Monitor renal and thyroid function and aim for a therapeutic serum range, adjusting for age and medical comorbidities.
• Valproate is preferred in rapid cycling and mixed states but is highly teratogenic, associated with neural tube defects and other congenital anomalies; use with extreme caution in women of reproductive age.
• Lamotrigine is better for bipolar depression and maintenance than for acute mania; titrate slowly to reduce risk of serious rash.
• Atypical antipsychotics such as quetiapine, lurasidone, and others play dual roles in treating acute episodes and maintenance but require monitoring for metabolic side effects.
• Rapid cycling (≥4 episodes/year) is associated with poorer prognosis and may be triggered or worsened by antidepressant use, substance use, and thyroid dysfunction.
• Mixed features represent a high‑risk state for impulsivity and suicide and can be more challenging to treat; mood stabilizers and antipsychotics are preferred over antidepressants.
• Assess for comorbidities (anxiety, ADHD, substance use) as they impact treatment choices and prognosis.
• In any patient with recurrent depression, ask specifically about periods of increased energy, decreased sleep, and risky behavior to screen for unrecognized bipolar disorder.

Summary

Bipolar disorder is a chronic, highly heritable mood disorder defined by recurrent episodes of mania/hypomania and depression. Accurate diagnosis requires careful longitudinal history and distinction from unipolar depression, substance‑induced mood changes, and other psychiatric disorders. Treatment is centered around mood stabilizers and atypical antipsychotics, with antidepressants used cautiously and usually only in combination. Long‑term maintenance therapy, psychosocial interventions, and ongoing monitoring for relapse and side effects are essential to optimize outcomes and reduce the high burden of suicide and functional impairment.